Tms (4891) · PolicyRestated
R&D Priority and No Dividends for the Time Being
First written in FY2023. 6 of 7 entries say "Restated". Latest entry: FY2027-H1.
7entries
4years
0from disclosures
How it moved
Same theme, other companies
No-Dividend Policy Prioritizing R&D FundingA theme 36 companies write about · 8 as a headwind · 19 as a tailwind
The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 36 companies compared. The sentences above are computed from all 36.Full recordFilings, disclosures and news, newest first
- FY2027-H1RestatedAnnual report
「1. Dividends paid Not applicable.」
No dividends were paid during the interim accounting period, and the Company continued to pay no dividends. - FY2026-H1RestatedAnnual report
「1. Dividends paid: Not applicable.」
No dividends were paid during the interim accounting period, and the Company continued to pay no dividends. - FY2025RestatedAnnual report
「No dividend was paid for the fiscal year in order to secure R&D funding through retained earnings.」
The Company continued to prioritize retaining funds for R&D and did not pay a dividend for the fiscal year. - FY2025-H1RestatedAnnual report
「1. Dividends paid: Not applicable.」
No dividends were paid during the interim accounting period, and the Company continued to pay no dividends. - FY2025-Q1RestatedAnnual report
「1. Dividends paid: Not applicable.」
No dividends were paid during the first quarter, and the Company remained non-dividend-paying. - FY2024-Q3RestatedAnnual report
「Dividend per share (¥): —」
No dividends were paid during the first nine months, and dividend per share remained zero. - FY2023First statedAnnual report
「For the time being, the Company plans to pay no dividends in order to pursue active pharmaceutical R&D and intends to allocate all retained earnings to R&D.」
The Company prioritizes retaining funds for R&D and plans to pay no dividends for the time being. It will consider returning profits to shareholders after launches and profits are achieved.